Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -2 of 2
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
2/29/2008
 
First Published:
2/1/1999
1.
Phase I Study of Recombinant BL22 Immunotoxin in Patients With Refractory or Recurrent CD22+ Hairy Cell Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
NCI
NCI-99-C-0014
NCI-T98-0063, NCT00021983
Last Modified:
2/29/2008
 
First Published:
7/23/2005
2.
Phase I Study of Recombinant BL22 Immunotoxin in Patients With CD22-Positive Refractory B-Cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Indolent Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
NCI, Pharmaceutical / Industry
NCI-05-C-0171
NCI-P6620, NCI-5336, NCT00126646
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute